PROTACT- A Clinical Trial That Targets Pancreatic Cancer
For Patients With Pancreatic Cancer
Find Out If You Can Participate PROTACT
Your Treatment is Our Goal
If you or your loved one has recently been diagnosed with stage III Pancreatic cancer
We would like to invite you to participate in a clinical trial fighting pancreatic cancer, providing hope for you and many other new patients.
PROTACT, stands for Precise RNAi for Obtaining Targeted Cancer Therapy, is the acronym selected for this Phase II clinical trial, now recruiting in several medical centers in the USA and in Israel. Previous results from Phase I have shown promising outcomes, suggesting that combining the novel “siG12D-LODER” drug with standard chemotherapy may be very effective in patients with locally advanced pancreatic cancer.
This study is open for patients who have recently been diagnosed with stage III Pancreatic Cancer (with no appearance of metastases) and were not scheduled for tumor surgery.
For Healthcare Professionals
Your Patients Come First
Learn How Clinical Trials Can Help
Pancreatic cancer patients who participate in clinical trials are provided with the best treatment options, receiving early access to cutting-edge treatments that progress research, and improve treatment options overall benefiting better care during treatment and far better outcomes.
The PROTACT trial number is NCT01676259, it appears and being updated routinely in the ClinicalTrials.gov website
PROTACT offers a novel treatment that targets the main pancreatic cancer driver, the oncogene called KRAS, which so far (prior to this study) is considered ‘undruggable’. KRAS is mutated in 95% of pancreatic cancer patients. The siG12D-LODER encompasses the anti-KRAS(mutated) drug. It enables precise RNAi-based silencing and it induces death of the KRAS oncogene; The Silenseed’s LODER (LOcal Drug EluteR) platform can be customized per indication. LODER is optimized to release drug very slowly at a controlled rate, enabling very effective drug distribution over the entire tumor. For pancreatic cancer we have found the release period of 12 weeks to be the optimal.
Treatment & Benefits
Targeting Pancreatic Cancer
From Science To Prospect- Treatment & Benefits
About The Treatment
The siG12D-LODER treatment is provided every 12 weeks. During treatment, a miniature biodegradable polymeric matrix called “LODER” that encompasses an anti KRAS(G12D) drug is inserted directly into the core of the solid tumor, using a standard Endoscope Ultrasound (EUS) procedure. Insertion usually does not require full anesthesia, and normally can take about a quarter of an hour. Immediately after insertion the LODER start releasing the siG12D drug slowly in a controlled manner over 12-16 weeks. Recent studies have shown that in addition to extending overall progression-free survival, the LODER treatment may halt perineural invasion (PNI) and by that may reduce the development of pain (usually in the abdomen or back) in patients with pancreatic cancer .
Patients who participate in clinical research have better outcomes. All revolutionary treatments available today were approved initially through clinical trials.
The siG12D-LODER tested in PROTACT is safe for use and has minimal or no side effects at all.
All participants in the PROTACT clinical trial receive personal hands-on advice, care, and support from professional and trained clinical staff who understand the patients’ disease and their condition.
All participants in the PROTACT clinical trial are checked and monitored closely on a regular basis and receive much more personal attention than patients who receive chemotherapy through regular oncology clinics.
PROTACT offers patients the opportunity to receive the latest treatments available today. Our treatments may significantly improve patient condition and provide hope to all future patients with pancreatic cancer.
About Our Physicians
Memorial Sloan Kettering Cancer Center
Eileen M. O’Reilly, MD
Medical Oncologist, Associate Director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research
Mark A. Schattner, MD, FASGE, AGAF
Chief, Gastroenterology, Hepatology and Nutrition Service
Anna M. Varghese, MD
Board-certified medical oncologist who specializes in the care of patients with gastrointestinal cancers and cancers of unknown primary origin
MD Anderson Cancer Center, Houston, TX
Milind Javle, M.D.
Medical Oncologist, Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
Manoop S. Bhutani, MD
Professor of Medicine (with tenure), Department of Gastroenterology, Hepatology & Nutrition, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Mount Sinai Hospital
Celina Ang, MD
Assistant professor | Medicine, Hematology and Medical Oncology
Christopher J. DiMaio, MD, FACG, FASGE, NYSGEF
Director of Therapeutic Endoscopy
Hackensack Meridian, NJ
Martin Gutierrez, MD
Specializes in medical oncology, thoracic and gastrointestinal oncology, and is board certified in internal medicine, medical oncology and hematology
Rosario Ligresti, MD, FASGE
Gastroenterologist, Internal Medicine
Specializes in the diagnosis and treatment of digestive cancers, particularly cancers of the pancreas and bile duct